1 acid (CMP-NANA) to increase LPS sialylation, convalescent-phase serum bactericidal titers were decrea

2 Antibody to rDR2/Fic or passively protective convalescent-phase serum blocked IbpA-mediated cytotoxic

3                                              Convalescent-phase serum collected from a GII.4.2009 out

4 eutralization of GI VLPs was demonstrated by convalescent-phase serum cross-blockade of GI VLP-HBGA i

5                                              Convalescent-phase serum from a patient with an active G

6 era from infected/vaccinated guinea pigs and convalescent-phase serum from human patients who had rec

7                                              Convalescent-phase serum from humans following clinical

8  1996 using a large collection of acute- and convalescent-phase serum pairs (n = 298) collected from

9  to test acute, convalescent phase, and post-convalescent phase serum/plasma samples from reverse-tra

10 f these patients without the submission of a convalescent-phase serum sample.

11 sis--specific 31-kD antigen were detected in convalescent-phase serum samples from 11 patients.

12  The geometric mean titers of the acute- and convalescent-phase serum samples measured by IFA were 1:

13                                   Acute- and convalescent-phase serum samples obtained from 42 patien

14                                     All nine convalescent-phase serum samples tested had neutralizing

15 ing titer were observed when acute-phase and convalescent-phase serum samples were compared (168 [44%

16          Our findings were validated using a convalescent-phase serum specimen from a patient infecte

17  LD-endemic areas to provide acute- (S1) and convalescent-phase serum specimens (S2).